Skip to content
naulon
Get started

Not checked for notices yet.

SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study

Jessica Brehm, Alexander Spaeth, Lars Dreßler and 6 more

Frontiers in Immunology · 2022

doi:10.3389/fimmu.2022.915338

References 78

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.
    The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection · 2020
    No notice
  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.
    Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients · 2020
    No notice
  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.
    Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
    No notice
  20. 20.
    The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients · 2020
    No notice
  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.
    Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients · 2020
    No notice
  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.
    A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity · 2020
    No notice
  34. 34.
    Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection · 2020
    No notice
  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.
    Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients · 2020
    No notice
  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.
    Robust neutralizing antibodies to SARS-CoV-2 infection persist for months · 2020
    No notice
  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  51. 51.
    Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays · 2021
    No notice
  52. 52.
    Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection · 2021
    No notice
  53. 53.
    Long COVID in a prospective cohort of home-isolated patients · 2021
    No notice
  54. 54.
    Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination · 2021
    No notice
  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  71. 71.
    Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study · 2022
    No notice
  72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  73. 73.
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination · 2022
    No notice
  74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  77. 77.
    Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome · 2022
    No notice
  78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.